Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma
- PMID: 33416909
- DOI: 10.1007/s00280-020-04220-y
Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma
Abstract
Purpose: Vincristine (VCR) is a key drug for treating various malignancies. However, few data are available on the pharmacokinetics of VCR, especially in adult patients. The objective of this study was to clarify the population pharmacokinetics and exposure-response relationships of VCR in adult malignant lymphoma patients.
Methods: Blood samples were collected from patients who were administered R-CHOP-like regimens, and the VCR plasma concentration was determined using liquid chromatography-mass spectrometry. Using NONMEM software, population pharmacokinetic parameters were estimated, and covariates were evaluated. The relationships between the individual parameters and adverse events or therapeutic effects were also investigated.
Results: Plasma concentrations were measured in 30 patients. In the final population pharmacokinetics model, body surface area and age were incorporated into clearance as significant covariates. The inter-individual variations in clearance and volume of distribution in the central and third compartments were 17.0, 26.6, and 66.3%, respectively, and the residual variability in the plasma concentration was 23.8%. Although the variability observed in the volume of distribution was large, good predictability was obtained in the individual estimation. The severity of anemia and peripheral neuropathy was correlated with clearance and peak concentration, respectively (adjusted P = 0.040 and 0.024, respectively). In diffuse large B cell lymphoma patients, those with higher area under the curve and dose experienced longer progression-free survival (P = 0.023 and 0.013, respectively).
Conclusion: The population pharmacokinetics of VCR were evaluated in adult malignant lymphoma patients. VCR pharmacokinetic data could explain in part the adverse events and prognosis of these patients.
Keywords: Malignant lymphoma; Pharmacodynamics; Population pharmacokinetics; Vincristine.
Similar articles
-
Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.Cancer Chemother Pharmacol. 2019 Apr;83(4):775-785. doi: 10.1007/s00280-019-03775-9. Epub 2019 Jan 28. Cancer Chemother Pharmacol. 2019. PMID: 30689002
-
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314734
-
Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.Acta Pharmacol Sin. 2012 Jun;33(6):852-8. doi: 10.1038/aps.2012.44. Acta Pharmacol Sin. 2012. PMID: 22669119 Free PMC article. Clinical Trial.
-
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Cancer Chemother Pharmacol. 2013. PMID: 23212117 Free PMC article. Review.
-
Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts.Arch Toxicol. 2023 Feb;97(2):377-392. doi: 10.1007/s00204-022-03418-8. Epub 2022 Nov 23. Arch Toxicol. 2023. PMID: 36418572 Review.
Cited by
-
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.ESMO Open. 2024 Dec;9(12):104002. doi: 10.1016/j.esmoop.2024.104002. Epub 2024 Dec 10. ESMO Open. 2024. PMID: 39662226 Free PMC article.
-
LCT-3d Induces Oxidative Stress-Mediated Apoptosis by Upregulating Death Receptor 5 in Gastric Cancer Cells.Front Oncol. 2021 Apr 16;11:658608. doi: 10.3389/fonc.2021.658608. eCollection 2021. Front Oncol. 2021. PMID: 33937072 Free PMC article.
-
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.Clin Pharmacokinet. 2024 Feb;63(2):197-209. doi: 10.1007/s40262-023-01336-1. Epub 2023 Dec 23. Clin Pharmacokinet. 2024. PMID: 38141094 Free PMC article.
-
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.Cancer Chemother Pharmacol. 2023 Nov;92(5):391-398. doi: 10.1007/s00280-023-04580-1. Epub 2023 Aug 23. Cancer Chemother Pharmacol. 2023. PMID: 37610625
References
-
- Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265. https://doi.org/10.1038/nrc1317 - DOI - PubMed
-
- van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH (2017) Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol 114:114–130. https://doi.org/10.1016/j.critrevonc.2017.04.004 - DOI - PubMed
-
- Sethi VS, Jackson DV Jr, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Can Res 41(9 Pt 1):3551–3555
-
- Vendrig DE, Teeuwsen J, Holthuis JJ (1988) Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 424(1):83–94. https://doi.org/10.1016/s0378-4347(00)81078-6 - DOI - PubMed
-
- Ramírez J, Ogan K, Ratain MJ (1997) Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol 39(4):286–290. https://doi.org/10.1007/s002800050574 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials